摘要
目的:探讨TCF4和E-cadherin在卵巢癌中的表达意义。方法:采用免疫组化SP法检测19例卵巢良性囊腺瘤、19例交界性囊腺瘤、50例恶性肿瘤中TCF4和E-cadherin的表达。结果:TCF4在卵巢癌组织、交界性肿瘤中表达明显高于良性囊腺瘤组织(P<0.05),阳性率分别为76%、63.2%、31.6%。E-cadherin在卵巢良性、交界性肿瘤、卵巢癌中阳性率分别为78.9%、52.6%、36.0%。E-cadherin在卵巢交界性肿瘤及卵巢癌组织中表达明显低于良性肿瘤组织(P<0.05)。E-cadherin及TCF4表达与卵巢癌患者年龄无关(P>0.05),TCF4表达与卵巢癌病理学分级、FIGO分期有关(P<0.05)。结论:TCF4在卵巢癌中表达高于卵巢良性肿瘤和交界性肿瘤,同时与卵巢癌病理学分级、FIGO分期成正相关。而E-cadherin在卵巢癌中表达低于卵巢良性肿瘤和交界性肿瘤,同时与卵巢癌病理学分级、FIGO分期负相关。
Objective ： To explore the expression of TCF4 and E - cadherin in ovarian cancer and the significance. Methods：Immunohistochemistry was used to detect the expression of E - cadherin and TCF4 in 19 cases of ovarian benign cystadenomas, 19 cases of borderline cystadenomas and 50 cases of ovarian cancer. Results ：Immunohistochemical staining was scored which showed the expression of TCF4 in ovarian cancer, borderline eystadenomas was higher than benign eystadenomas（P 〈 0.05 ）. The positive rates of TCF4 were 76% ,63.2% and 31.6% respectively. The positive rates of E - cadherin in benign eystadenomas, borderline cystadenomas, ovarian carcinoma were 78.9% , 52.6% and 36.0% respectively. The expression of E - cadherin in ovarian borderline carcinoma and ovarian cancer was obviously lower than that of benign cystadenoma tissues （ P 〈 0.05 ）. The expression of E - cadherin and TCF4 had no relation with the ovarian cancer patients＇age （P 〉 0.05 ）. The expression of TCF4 was associated with ovarian cancer pathology classification, FIGO stage （P 〈 0.05 ）. Conclusion： TCF4 expression in ovarian cancer was higher than that in borderline cystadenomas and benign cystadenomas, at the same time, there was a positive correlation with the pathology classification and FIGO stage. E - cadherin expression in ovarian cancer was lower than that in border- line cystadenomas and benign cystadenomas, and there was a negative correlation with the pathology classification and FIGO stage.
出处
《现代肿瘤医学》
CAS
2016年第1期123-126,共4页
Journal of Modern Oncology
基金
安徽省科技计划项目(编号:1402052075)
